UnitedHealth Group Incorporated (UNH) $403.97
UnitedHealth is currently caught in a technical no-man’s land, sitting 12.5% below its 52-week high while institutional ‘smart money’ waits for a definitive floor.
52-wk High $461.62
📌 Investment Snapshot
- Price of $403.97 trades at a 31.1x P/E, reflecting a significant premium to the broader managed care sector.
- Q1 2026 revenue hit $111.72B with EPS of $6.92, showing resilience despite 2025’s volatile bottom-line performance.
- The 17.6% consensus upside is countered by a bearish MACD crossover and price action below the SMA50.
- Mean analyst target of $475.23 suggests long-term confidence despite the recent 5.7% monthly slide.
⏳ WAIT
UNH is currently searching for support as it retreats toward the $390 level. While fundamentals remain robust, the technical breakdown below the 50-day moving average demands patience before committing new capital.
| 📍 Entry Zone | $394.00 or below | 🛑 Stop-Loss | $375.00 |
| 📋 Adjust If | Price reclaims $412.00 on high volume | ||
The Investment Case — Why Now?
The narrative around UnitedHealth has shifted from pure growth to margin stabilization over the last 90 days. After a turbulent 2025 marked by EPS volatility, the Q1 2026 print of $6.92 signaled a return to operational normalcy. However, the market remains skeptical of the 31x multiple in a 4.67% Treasury yield environment.
Regulatory scrutiny on Medicare Advantage rates continues to be the primary headwind for the remainder of 2026. We estimate that every 100 basis point shift in medical loss ratios (MLR) could impact annual EPS by approximately $0.85. This sensitivity explains why the stock is struggling to maintain its premium valuation despite strong free cash flow.
🤔 Can UnitedHealth justify a 31x P/E if Medicare Advantage margins continue to compress under federal pressure?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Healthcare Plans |
| Dividend Yield | 2.25% |
| Employees | 440,000 |
Open chart on TradingView →
📈 Price Action & Technicals
Dead Cross
Inside VA
Buy-side Sweep at $411.29 on 2026-08-04
UNH currently trades below its SMA50 ($411.75), confirming a short-term bearish trend that overrides the long-term SMA200 support. The price is effectively sandwiched between these two major averages, suggesting a period of consolidation is likely. A decisive close above the SMA50 is required to flip the technical bias back to bullish.
The RSI at 37.5 signals building selling pressure, yet it hasn’t reached the ‘capitulation’ levels below 30 that typically precede a sharp bounce. Meanwhile, the ADX at 26.2 combined with a dominant -DI of 29.9 confirms that the current downtrend has significant strength. Momentum remains firmly in the bears’ camp for now.
Anchored VWAP from one year ago sits way down at $327.54, indicating that the ‘average’ long-term holder is still deep in the green. This creates a risk of further profit-taking if the $400 psychological level fails to hold. The Volume Profile Point of Control at $283.51 is too distant to serve as a relevant magnet, but it highlights the lack of recent high-volume support.
Recent liquidity sweeps at $411.29 and $412.54 show that every attempt to rally is being met by aggressive selling. These ‘buy-side sweeps’ suggest that institutional players are using minor bounces to exit or hedge positions. We see a clear ceiling of resistance forming just above the current price action.
Historically, UNH tends to find buyers when it fills bullish Fair Value Gaps (FVG). We are closely watching the $385.26 to $394.94 zone, which remains unfilled from June. A dip into this pocket would likely trigger the Technical Confluence Score of 90, providing a high-probability entry point.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| UNH | UnitedHealth Group | 31.1x |
| ELV | Elevance Health | 18.4x |
| CVS | CVS Health | 11.2x |
| HUM | Humana Inc. | 22.5x |
| SPY | S&P 500 Avg | 21.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q1 2026 | $111.72B | $6.92 | +4.5% |
| Q4 2025 | $113.22B | $0.01 | -99.8% |
| Q3 2025 | $113.16B | $2.59 | -15.2% |
| Q2 2025 | $111.62B | $3.76 | -8.4% |
UnitedHealth generated a robust $8.1B in Free Cash Flow in the latest quarter, supporting its 2.25% dividend yield and ongoing share repurchases.
The massive EPS dip in late 2025 was a localized event, but the subsequent recovery to $6.92 in Q1 2026 proves the core Optum and UnitedHealthcare engines are still firing. Revenue remains remarkably stable above the $110B per quarter threshold.
🚀 Growth Drivers — What Moves the Stock
- Optum Health Expansion 🟢 Upside Surprise — Continued shift toward value-based care models is driving higher per-member revenue across the Optum ecosystem.
- Medicare Advantage Enrollment 🟡 Priced In — Market share gains in the senior segment are expected to offset lower federal reimbursement rates in 2027.
- Pharmacy Benefit Management 🟡 Priced In — OptumRx is leveraging scale to maintain margins despite increasing legislative pressure on PBM transparency.
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Blackrock Inc. | 73,467 |
| Vanguard Capital Management LLC | 58,870 |
| State Street Corporation | 45,332 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| BAKER CHARLES D | Director | 2026-07-01 | Purchase | 220 |
| MCNABB FREDERICK | Director | 2026-07-01 | Purchase | 250 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 2.1% | 2.9 |
⚠ Key Risk Factors
~$2.5B impact
Regulatory risk
🤔 With the 10Y Treasury at 4.67%, does UNH’s 2.25% yield provide enough of a safety net for income investors?
🎯 Guidance & Wall Street View
Management maintains a long-term EPS growth target of 13-16%, though recent quarters have seen significant variance from this trend.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $529.00 | $475.23 | $313.00 | 26 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| JP Morgan | Overweight | $475 | 2026-07-21 | Maintained |
| Mizuho | Outperform | $485 | 2026-07-21 | Maintained |
Wall Street remains overwhelmingly bullish with 26 analysts maintaining a ‘Buy’ consensus, viewing the current dip as a valuation reset rather than a fundamental breakdown.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Optum’s data-driven care delivery continues to outpace traditional insurance growth.
- Aggressive share buybacks and dividend growth provide a floor for total shareholder returns.
📊 Base Case
UNH trades sideways as it digests regulatory headwinds and stabilizes its 2026 EPS trajectory.
🐻 Bear Case
- A breach of the $375 support level could trigger a technical cascade toward the SMA200.
- Medicare Advantage margin compression proves more permanent than transitory.
🎯 Investor Action Plan — By Profile
Avoid catching the falling knife here. Wait for a touch of the $394 FVG zone or an RSI reversal above 40 before entering for a bounce toward $425.
The Technical Confluence Score of 90 is high, but the price is still above the optimal Entry Zone. Let the stock settle near $395 to maximize your risk-reward ratio.
Core fundamentals and cash flow remain elite. Maintain your current position but defer new additions until the technical downtrend shows signs of exhaustion.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Why is UNH stock falling despite a 'Buy' rating from analysts?
The decline is primarily technical and macro-driven, as the stock trades below its 50-day moving average and faces pressure from rising Treasury yields.
Q: What is the key support level to watch for UNH?
The $385.26 to $394.94 Fair Value Gap (FVG) is the most critical support zone where institutional buyers are expected to step in.
Q: Is the 2.25% dividend yield safe?
Yes, with $8.1B in quarterly free cash flow and a manageable payout ratio, the dividend remains one of the safest in the healthcare sector.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 For real-time updates and advanced charting tools,
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. UnitedHealth Group’s past performance is not indicative of future results.
All active positions and their real-time performance are tracked on our Investment Log.
#UNH #UnitedHealth #HealthcareStocks #StockMarket #Investing #WallStreet #TechnicalAnalysis